首页> 外文期刊>The Journal of Nuclear Medicine >18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.
【24h】

18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups.

机译:胸腺上皮肿瘤的18F-FDG PET / CT:用于区分和分期肿瘤亚组的有用性。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of our study was to assess the usefulness of integrated PET/CT using 18F-FDG for distinguishing thymic epithelial tumors according to the World Health Organization (WHO) classification. METHODS: Thirty-three patients (age range, 34-68 y; mean age, 54.6 y) with thymic epithelial tumors, who underwent both integrated PET/CT and enhanced CT, were included. The clinicopathologic stages, maximum standardized uptake values (SUVs), and uptake patterns of tumors on integrated PET/CT images, and various enhanced CT findings, are described according to the simplified (low-risk [types A, AB, and B1] and high-risk [types B2 and B3] thymomas and thymic carcinomas) subgroups of the WHO classification. Discriminant analysis was performed to determine the relative capabilities of integrated PET/CT and enhanced CT findings to differentiate tumor subgroups. RESULTS: Tumors included 8 low-risk thymomas, 9 high-risk thymomas, and 16 thymic carcinomas. The maximum SUVs of high-risk thymomas (P < 0.001) and low-risk thymomas (P < 0.001) were found to be significantly lower than those of thymic carcinomas. Homogeneous 18F-FDG uptake within tumors was more frequently seen in thymic carcinomas than in high-risk thymomas (P = 0.027) or low-risk thymomas (P = 0.001). The uptake pattern (homogeneous vs. heterogeneous) on integrated PET/CT images and the presence of mediastinal fat invasion on enhanced CT images were found to be useful for differentiating tumor subgroups. In addition, integrated PET/CT helped detect lymph node metastases, which were not identified on enhanced CT in 2 patients. CONCLUSION: Integrated PET/CT was found to be useful for differentiating subgroups of thymic epithelial tumors and for staging the extent of the disease.
机译:我们的研究目的是根据世界卫生组织(WHO)的分类评估使用18F-FDG的PET / CT集成在区分胸腺上皮肿瘤中的有用性。方法:纳入33例同时行PET / CT和增强CT检查的胸腺上皮肿瘤患者(年龄范围34-68岁;平均年龄54.6岁)。根据简化的(低风险[A,AB和B1型]和[1]型),描述了临床病理分期,最大标准摄取值(SUV)和整合PET / CT图像上肿瘤的摄取模式以及各种增强的CT表现。 WHO分类的高危[B2和B3型]胸腺瘤和胸腺癌)亚组。进行判别分析以确定整合的PET / CT和增强的CT表现来区分肿瘤亚组的相对能力。结果:肿瘤包括8例低危胸腺瘤,9例高危胸腺瘤和16例胸腺癌。发现高危胸腺瘤(P <0.001)和低危胸腺瘤(P <0.001)的最大SUVs明显低于胸腺癌。与高危胸腺瘤(P = 0.027)或低危胸腺瘤(P = 0.001)相比,在胸腺癌中更常见于肿瘤内的同质18F-FDG摄取。发现整合PET / CT图像上的摄取模式(均质与异质)以及增强的CT图像上存在纵隔脂肪浸润可用于区分肿瘤亚组。此外,集成的PET / CT有助于检测淋巴结转移,这在2例患者的增强CT中未发现。结论:集成的PET / CT被发现可用于区分胸腺上皮肿瘤的亚组和分期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号